特发性肺纤维化疾病进展保守序列的识别
研究纳入245例家族性肺纤维化成人和347例安慰剂治疗的IPF患者,用贝叶斯联合重复测量模型描述肺功能随估计发病年数变化。发现DLCO约在发病前10年开始下降,FVC下降较晚,发病后5年内FVC年降幅显著增大,死亡或移植风险随发病年数增加而升高。
要点
- IPF肺功能呈序贯性下降:DLCO先降,FVC后降。
- 发病后5年内FVC年降幅显著大于发病前5年。
- 估计发病年数每增加1年,死亡或移植风险升高31%。
核心结论
- IPF存在保守的序贯性肺功能下降模式,对临床试验设计有重要意义。
研究设计与样本
- 两个队列:245例亚临床至晚期家族性肺纤维化成人,及347例来自2项随机对照试验的安慰剂治疗IPF患者。
- 采用贝叶斯联合重复测量模型,以估计发病年数描述肺功能变化,并假设DLCO为70%预计值时发病。
主要发现
- 家族性肺纤维化队列中,DLCO约从估计发病前10年开始稳定下降,发病前5年达86.8%预计值,发病后5年达45.3%预计值。
- FVC下降较晚,发病前5年达98.6%预计值,发病后5年达76.2%预计值。
- 发病后5年时FVC年降幅为6.14%预计值,发病前5年时为0.49%预计值,前者为后者的12倍。
- 估计发病年数每增加1年,死亡或移植风险HR为1.31(95%CI 1.25-1.37)。
- 随机对照试验队列中观察到相似结果。
临床怎么用
- 可利用DLCO和FVC的序贯下降模式辅助IPF早期识别与病情监测。
- 临床试验设计可参考估计发病年数分层,以捕捉不同阶段的肺功能变化速率。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
RATIONALE: Idiopathic pulmonary fibrosis (IPF) begins years before symptoms appear, but the natural history is incompletely understood. OBJECTIVES: To describe and quantify IPF disease progression using 4 pulmonary function test (PFT) parameters. METHODS: Two cohorts included 245 adults with subclinical through advanced familial pulmonary fibrosis (FPF) or 347 placebo-treated IPF patients enrolled in 2 randomized controlled trials (RCTs). A Bayesian joint repeated measures model was fit to describe the observed PFT values as a function of the estimated years since onset (EYO). A latent variable estimated the subject-level chronological age at onset. Onset was assumed to occur when the diffusion capacity for carbon monoxide (DLCO) was 70%-predicted. The relationships between EYO and clinical outcomes not included in the model (eg, transplant-free survival) were evaluated, adjusting for age and sex. MEASUREMENTS AND MAIN RESULTS: In FPF, the DLCO declined steadily starting around EYO -10, reaching 86.8%-predicted by EYO -5 and 45.3%-predicted by EYO +5. The forced vital capacity (FVC) declined later, reaching 98.6%-predicted by EYO -5 and 76.2%-predicted by EYO +5. The annualized decline in FVC was 12-fold greater in the year after EYO +5 (6.14%-predicted) than EYO -5 (0.49%-predicted). There was a 31% higher risk of death or transplant (HR, 1.31 [95% CI, 1.25-1.37]) per 1-year increase in EYO. Similar findings were observed in the RCTs. CONCLUSIONS: We identified a conserved sequential decline in lung function in IPF, which has important implications for the design of clinical trials. The disease progression model provides a powerful framework to investigate the clinical and/or biological processes that initiate and propagate IPF.
引用
- Huang X, Wu P, Guttentag AR, et al. Identification of a conserved sequence of disease progression in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med. 2026. PMID: 41738263. doi:10.1093/ajrccm/aamag075
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。